Page 2 - Pharmaceutical

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

USFDA issues 6 observations to Zydus' Gujarat API unit after inspection

Zydus Lifesciences on Saturday said the US health regulator has issued six observations after inspecting its Gujarat-based API manufacturing unit. "We wish to inform that the US Food and Drug Administration (USFDA) conducted a surveillance inspection at the group's API (active pharmaceutical ingredient) unit located at Dabhasa in Gujarat," the drug firm said in a regulatory filing. The inspection was conducted from April 21-25, 2025. "The inspection concluded with 6 observations and none of them were related to data integrity," Zydus Lifesciences said. The company is confident of addressing the observations expeditiously, it added.

Eli Lilly's first weight-loss pill shows success in initial Phase 3 trials

Lilly CEO says if approved, drug could be manufactured and launched at scale globally

US tops India's pharma exports with $9.8 bn share in April-Feb FY25

Exports to the US grew 14% in April-February FY25

Emcure arm Tillomed acquires Manx Pharma portfolio for Rs 218.67 cr

The deal includes the purchase of product dossiers, marketing authorisations, intellectual property, and inventory

Peter Bains steps down as Group CEO of Biocon, to serve Syngene's MD & CEO

Furthermore, Biocon has scheduled a board meeting on April 4 to discuss and approve fundraising for its commercial business

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences

As per the scheme's terms, the merger will take effect from the first business day of the month following the fulfilment of all conditions

Diarrhoea and viral infections spur sales of probiotics, shows data

Antidiarrheals and anti-flatulents have also grown in strong double digits - 36 per cent and 29 per cent, respectively

Towards greener GST: Rationalisation must align with jobs, sustainability

GST rate rationalisation and expansion must be done not only to achieve simplification but also to subserve large-scale employment and environmental policy goals

Indian pharmaceutical exports ranked 11th globally in 2023: Anupriya Patel

Indian pharmaceutical exports ranked 11th globally in value terms in 2023 and accounted for 3 per cent of the total pharmaceutical exports, Union Minister Anupriya Patel said in Rajya Sabha on Tuesday. The Union Minister of State for Chemicals and Fertilisers gave the information in a written reply to the House, citing a secondary market research analysis published by Bain and Company this year. Replying to a query on whether the quality of Indian pharmaceutical products has often been questioned in some global markets, the minister said the Central Drugs Standard Control Organisation (CDSCO) and Ministry of Health and Family Welfare have taken several measures to ensure quality, safety and efficacy of medicines. To another question, Patel said the mobile app of National Pharmaceuticals Pricing Policy (NPPP), Pharma Sahi Daam (PSD) provides brand name, composition, ceiling price and maximum retail price of drugs for consumer benefit and transparency. She said the entire procedure

Indian pharma market registers 7.5% growth in Feb 2025: Pharmarack

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, and 6 per cent, respectively

Distributed manufacturing may become the future trend: Pharma Inc

Volumes need to be high to justify relocation of manufacturing; strategic decisions cannot be based on current tariff structure

DCGI streamlines drug export approval, plans revised biosimilar guidelines

Previously, companies exporting drugs from India had to apply for a customer- and quantity-specific NOC each time they received an order

MO Alts acquires majority stake in Megafine Pharma for Rs 460 crore

Megafine currently operates two USFDA-approved manufacturing facilities located in Nashik, Maharashtra, and Vapi, Gujarat, and specialises in niche, high-margin APIs, primarily used in chronic disease

CDSCO withdraws export NOC, bans drugs linked to West Africa opioid crisis

The ministry added that Aveo Pharmaceuticals has been issued a Stop Activity Order, halting all operations at the company's premises after a comprehensive audit

Pharma stocks plunge amid tariff concerns, but analysts see limited impact

Pharma stocks fell on Friday on concerns of tariff on imports

NPPA sets prices for 42 drugs, revises ceiling for 2 formulations

Prices have been fixed for drugs and formulations meant for diabetes, hypertension, heart issues, bacterial infections, allergies, and multivitamins

Commerce Ministry withdraws 'track and trace' rule for pharma exports

The Commerce Ministry on Friday said it has withdrawn the provisions related to the track and trace system for pharmaceutical exports under the foreign trade policy. The implementation of the authentication system for drug formulations being exported will be undertaken by the Ministry of Health and Family Welfare in line with the provisions under Drug Rules 1945, according to a public notice of the Directorate General of Foreign Trade (DGFT). "The DGFT has decided to streamline export regulations by aligning with the evolving regulatory framework of the Ministry of Health & Family Welfare. Accordingly, the provisions related to the track and trace system for pharmaceutical exports under the Foreign Trade Policy are being withdrawn," the ministry said. The system, introduced on January 10, 2011, mandated barcoding at various packaging levels. While tertiary and secondary packaging requirements were successfully implemented in 2011 and 2013, primary-level barcoding and parent-child .

OneSource sees surge in demand as semaglutide patents near expiry

The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with semaglutide formulations being a focal point

Mankind Pharma Q3FY25 results: PAT falls 16.5%, revenue rises 24%

Mankind's revenue from operations rose to Rs 3,230 crore in Q3FY25, a 24 per cent Y-o-Y rise from Rs 2,607 crore reported in Q3FY24